Hello NMPA: New English Website For China's Regulator, Inspection Scheme Bolstered
Executive Summary
China's main drug regulatory agency is hoping to tell its story to the world via a new English website, while the vaccines and other sectors are poised to see increasing quality inspections as the country builds up a new two-level scheme. Provincial reimbursement lists are also being halted.
You may also be interested in...
Hello NMPA: New Drug Approvals, Online Database And More
China grants approvals to Gilead’s HIV combo Biktarvy and Mitsubishi Tanabe Pharma’s Radicava in the latest batch of new product clearances. Meanwhile, a new online database for marketing authorization holders goes live.
Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement
China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.